Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab bioavailability study: on-body injector vs prefilled syringe
NCT07007091Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of risankizumab (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration of Risankizumab at 113 days, Time to Maximum Observed Plasma Concentration of Risankizumab at 113 days and 6 more. Started Jun 2025; status: completed.
02
Drugs
risankizumab
Beyond the preview
Go deeper on NCT07007091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007091.